Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, multi-centre, non-randomized, single arm study to evaluate the safety and efficacy of APCEDEN [Dendritic Cell (DC) immunotherapy] in patients with refractory solid malignancies, on symptomatic treatment - ATESST (Apceden Therapy: Efficacy and Safety in Solid Tumors)

Next Previous
X
Search
Trial Profile

An open label, multi-centre, non-randomized, single arm study to evaluate the safety and efficacy of APCEDEN [Dendritic Cell (DC) immunotherapy] in patients with refractory solid malignancies, on symptomatic treatment - ATESST (Apceden Therapy: Efficacy and Safety in Solid Tumors)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Autologous dendritic cell immunotherapy - APAC Biotech (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ATESST; ATTEST
  • Sponsors APAC Biotech; Semler Research Center

    • Most Recent Events

    • 13 Apr 2017 New trial record
    • 05 Apr 2017 Results published in an APAC Biotech Media Release
    • 05 Apr 2017 Dr. P P Bapsy was a Principal investigator of this trial, as reported in an APAC Biotech media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top